New pill shows promise for Hard-to-Treat transplant complication
NCT ID NCT04944043
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new tablet called TQ05105 in 45 adults with moderate to severe chronic graft-versus-host disease (cGVHD) that hasn't responded to steroids. The drug works by blocking a protein pathway involved in inflammation. The goal is to find the right dose and see if it can control the disease, potentially reducing the need for steroids.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQ05105 tablet (a JAK inhibitor)
What this could lead to
If successful, this could offer a new treatment option for people with chronic graft-versus-host disease that doesn't respond to steroids, helping control the condition and reduce steroid dependence.
What could go wrong
This is an early-phase trial with only 45 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangzhou First People's Hospital
Guangzhou, Guangdong, 511457, China
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, Tianjin Municipality, 300020, China
-
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, 510515, China
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Hefei, Anhui, 230001, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hanzhou, Zhejiang, 310000, China
-
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000, China
-
Tongji Hospital Tongji Medical College of HUST
Wuhan, Hubei, 430030, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510280, China